22.12.2020 08:15:00 CET | Monsenso | Company Announcement

Company Announcement no. 15-2020

Copenhagen, 2020.12.22

Monsenso has entered a new million-kroner agreement with a global pharmaceutical company and hereby expands its activities to six countries in the Middle East. As part of the agreement, Monsenso will provide its solution for patient monitoring and treatment support in the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar and Bahrain.

Monsenso's clinically validated solution will be used to support the treatment of depression and schizophrenia. Patients are provided with an app, which is used to collect real-time patient-reported information and to give patients access to information about their disorder between consultations. Clinicians gain access to a clinical web portal and can follow their patients remotely and gain valuable information about behavior, medication intake and symptoms. This enables clinicians to provide a data-driven treatment and allow for proactive follow-up.
In addition, the solution supports communication between patients and therapists.

“We are very pleased with this agreement, which contributes to both expanding our geographic market coverage and our business with pharmaceutical companies in line with our growth strategy. ” says Thomas Lethenborg, CEO of Monsenso. "Depression and schizophrenia are among the most costly disorders for society and have major consequences for affected patients and relatives. Therefore, we are proud to be able to contribute to better treatment within these disease areas."

Any inquiries regarding this notice should be directed to:

Monsenso:

CEO Thomas Lethenborg
Tel. +45 21 29 88 27
E-mail: lethenborg@monsenso.com 

Certified Adviser:

Norden CEF ApS
John Norden
Tel. +45 20 72 02 00

About Monsenso

Monsenso is an innovative technology company offering a mobile Health (mHealth) solution. Our mission is to help provide better mental health to more people at lower costs.  Our solution helps optimise the treatment of mental disorders and gives a detailed overview of an individual’s mental health through the collection of outcome, adherence and behavioural data. It connects individuals, carers and health care providers to enable personalised treatment, remote care and early intervention. Based on continuous research and development, our team is committed to developing solutions that fit seamlessly into the lives of individuals, increase their quality of life and improve the efficacy of mental health treatment. To learn more visit  www.monsenso.com

Attachments

• Download announcement as PDF.pdf